Gingival Crevicular Fluid Levels of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Glucosamine Sulphate Following its Adjunctive Use in Treatment of Chronic Periodontitis

Abstract

Based on the results of the present study, it could be concluded that: 1. Systemic glucosamine therapy for 3 months, as an adjunct to non surgical periodontal therapy might be an important addition to the therapeutic agents available for the management of generalized chronic periodontitis. 2. Glucosamine was bioavaliable in GCF and this could explain its beneficial effect in the management in chronic periodontitis by the presence of the drug in the local periodontal environment. 3. This study reflects the possible beneficial effects of glucosamine sulphate as a novel host response modulating agent in generalized chronic periodontitis patients via its inhibitory effect on RANKL level in GCF, since RANKL plays a key role in bone resorption in periodontal disease.